The drug is a joint venture between Bayer Healthcare Phamaceuticals and Johnson & Johnson. Johnson & Johnson has applied for approval for short-term use of the drug in the prevention of deep-vein thrombosis and pulmonary embolism in patients undergoing total hip and knee replacement surgery.
The company has recently finished clinical trials on the longer-term use of rivaroxaban in patients with acute coronary syndrome.
Read about the FDA panel’s recommendation to approve rivaroxaban.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
